| Literature DB >> 33364941 |
Ebenezeri Erasto Ngowi1,2,3, Muhammad Sarfraz1,2,4,5, Attia Afzal1,2,5, Nazeer Hussain Khan2,6, Saadullah Khattak1,2, Xin Zhang6,7, Tao Li1,2, Shao-Feng Duan2,6,7, Xin-Ying Ji1,2,8, Dong-Dong Wu1,2,9.
Abstract
Hydrogen sulfide (H2S) plays a key role in the regulation of physiological processes in mammals. The decline in H2S level has been reported in numerous renal disorders. In animal models of renal disorders, treatment with H2S donors could restore H2S levels and improve renal functions. H2S donors suppress renal dysfunction by regulating autophagy, apoptosis, oxidative stress, and inflammation through multiple signaling pathways, such as TRL4/NLRP3, AMP-activated protein kinase/mammalian target of rapamycin, transforming growth factor-β1/Smad3, extracellular signal-regulated protein kinases 1/2, mitogen-activated protein kinase, and nuclear factor kappa B. In this review, we summarize recent developments in the effects of H2S donors on the treatment of common renal diseases, including acute/chronic kidney disease, renal fibrosis, unilateral ureteral obstruction, glomerulosclerosis, diabetic nephropathy, hyperhomocysteinemia, drug-induced nephrotoxicity, metal-induced nephrotoxicity, and urolithiasis. Novel H2S donors can be designed and applied in the treatment of common renal diseases.Entities:
Keywords: H2S donors; common renal diseases; physiological process; renal dysfunction; signaling pathways
Year: 2020 PMID: 33364941 PMCID: PMC7751760 DOI: 10.3389/fphar.2020.564281
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810